Top

Published in:

01-02-2013

Possible Involvement of Toll-Like Receptors in the Pathogenesis of Myasthenia Gravis

Authors: Yu-Zhong Wang, Mei Yan, Fa-Fa Tian, Jun-Mei Zhang, Qun Liu, Huan Yang, Wen-Bin Zhou, Jing Li

Published in: Inflammation | Issue 1/2013

Abstract

Toll-like receptors (TLRs), the innate immunity components, have been demonstrated to participate in multiple autoimmune diseases. However, our knowledge of the roles of TLRs in myasthenia gravis (MG) is still scarce. In this study, we detected the mRNA expression of TLR1 to TLR10 in peripheral blood mononuclear cells (PBMCs) of MG patients and the healthy controls by quantitative real-time polymerase transcription chain reaction. Our data demonstrate that aberrant expressions of TLRs exist in the PBMCs of MG patients and of the total, expression level of TLR9 mRNA has significantly positive relation with the clinical severity of MG, which suggests that TLRs may be involved in the pathogenesis of MG.

Conti-Fine, B.M., M. Milani, and H.J. Kaminski. 2006. Myasthenia gravis: past, present, and future. The Journal of Clinical Investigation 116: 2843–2854.PubMedCrossRef

Lindstrom, J.M., M.E. Seybold, V.A. Lennon, S. Whittingham, and D.D. Duane. 1976. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26: 1054–1059.PubMedCrossRef

Hoch, W., J. McConville, S. Helms, J. Newsom-Davis, A. Melms, and A. Vincent. 2001. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine 7: 365–368.PubMedCrossRef

McGettrick, A.F., and L.A. O'Neill. 2007. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. British Journal of Haematology 139: 185–193.PubMedCrossRef

Zarember, K.A., and P.J. Godowski. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. The Journal of Immunology 168: 554–561.PubMed

Takeda, K. and S. Akira. 2007. Toll-like receptors. Current Protocols in Immunology. Chapter 14: Unit 14 12.

Kawai, T., and S. Akira. 2007. TLR signaling. Seminars in Immunology 19: 24–32.PubMedCrossRef

Medzhitov, R., P. Preston-Hurlburt, E. Kopp, A. Stadlen, C. Chen, S. Ghosh, and C.A. Janeway Jr. 1998. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Molecular Cell 2: 253–258.PubMedCrossRef

Devaraj, S., M.R. Dasu, J. Rockwood, W. Winter, S.C. Griffen, and I. Jialal. 2008. Increased Toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. The Journal of Clinical Endocrinology and Metabolism 93: 578–583.PubMedCrossRef

10.

Ehlers, M., H. Fukuyama, T.L. McGaha, A. Aderem, and J.V. Ravetch. 2006. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. The Journal of Experimental Medicine 203: 553–561.PubMedCrossRef

11.

Zeuner, R.A., K.J. Ishii, M.J. Lizak, I. Gursel, H. Yamada, D.M. Klinman, and D. Verthelyi. 2002. Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis and Rheumatism 46: 2219–2224.PubMedCrossRef

12.

Deng, Y.N., and W.B. Zhou. 2007. Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis. Neuroimmunomodulation 14: 337–343.PubMedCrossRef

13.

Wang, Y.Z., Q.H. Liang, H. Ramkalawan, Y.L. Wang, Y.F. Yang, W.B. Zhou, F. Tian, J. Li, and H. Yang. 2012. Expression of Toll-like receptors 2, 4 and 9 in Patients with Guillain-Barré syndrome. Neuroimmunomodulation 19: 60–68.PubMedCrossRef

14.

Wang, Y.Z., Q.H. Liang, H. Ramkalawan, W. Zhang, W.B. Zhou, B. Xiao, F.F. Tian, H. Yang, J. Li, Y. Zhang, and N.A. Xu. 2011. Inactivation of TLR9 by a suppressive oligodeoxynucleotides can ameliorate the clinical signs of EAN. Immunological Investigations 41: 171–182.PubMedCrossRef

15.

Bernasconi, P., M. Barberis, F. Baggi, L. Passerini, M. Cannone, E. Arnoldi, L. Novellino, F. Cornelio, and R. Mantegazza. 2005. Increased Toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. The American Journal of Pathology 167: 129–139.PubMedCrossRef

16.

Montero Vega, M.T., and A. de Andres Martin. 2008. Toll-like receptors: a family of innate sensors of danger that alert and drive immunity. Allergologia et Immunopathologia (Madr) 36: 347–357.CrossRef

17.

Jaretzki 3rd, A., R.J. Barohn, R.M. Ernstoff, H.J. Kaminski, J.C. Keesey, A.S. Penn, and D.B. Sanders. 2000. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16–23.PubMedCrossRef

18.

Osserman, K.E., and G. Genkins. 1971. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. The Mount Sinai Journal of Medicine 38: 497–537.

19.

Sharshar, T., S. Chevret, M. Mazighi, P. Chillet, G. Huberfeld, C. Berreotta, M. Houfani, and P. Gajdos. 2000. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. Journal of Neurology 247: 286–290.PubMedCrossRef

20.

Rozkova, D., R. Horvath, J. Bartunkova, and R. Spisek. 2006. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clinical Immunology 120: 260–271.PubMedCrossRef

21.

McCoy, C.E., S. Carpenter, E.M. Palsson-McDermott, L.J. Gearing, and L.A. O'Neill. 2008. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation. The Journal of Biological Chemistry 283: 14277–14285.PubMedCrossRef

22.

Roelofs, M.F., M.H. Wenink, F. Brentano, S. Abdollahi-Roodsaz, B. Oppers-Walgreen, P. Barrera, P.L. van Riel, L.A. Joosten, D. Kyburz, W.B. van den Berg, and T.R. Radstake. 2009. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Annals of the Rheumatic Diseases 68: 1486–1493.PubMedCrossRef

23.

Kessel, A., R. Peri, T. Haj, A. Snir, G. Slobodin, E. Sabo, I. Rosner, Y. Shoenfeld, and E. Toubi. 2011. IVIg attenuates TLR-9 activation in B cells from SLE patients. Journal of Clinical Immunology 31: 30–38.PubMedCrossRef

24.

Marta, M., A. Andersson, M. Isaksson, O. Kampe, and A. Lobell. 2008. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. European Journal of Immunology 38: 565–575.PubMedCrossRef

25.

Muzio, M., N. Polentarutti, D. Bosisio, P.P. Manoj Kumar, and A. Mantovani. 2000. Toll-like receptor family and signalling pathway. Biochemical Society Transactions 28: 563–566.PubMed

26.

Chow, J.C., D.W. Young, D.T. Golenbock, W.J. Christ, and F. Gusovsky. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. The Journal of Biological Chemistry 274: 10689–10692.PubMedCrossRef

27.

Lee, K.S., C.A. Scanga, E.M. Bachelder, Q. Chen, and C.M. Snapper. 2007. TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cellular Immunology 245: 103–110.PubMedCrossRef

28.

Krieg, A.M. 2002. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology 20: 709–760.PubMedCrossRef

29.

Riccardi, C., S. Bruscoli, and G. Migliorati. 2002. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacological Research 45: 361–368.PubMedCrossRef

30.

Chinenov, Y., and I. Rogatsky. 2007. Glucocorticoids and the innate immune system: crosstalk with the Toll-like receptor signaling network. Molecular and Cellular Endocrinology 275: 30–42.PubMedCrossRef

31.

Lepelletier, Y., R. Zollinger, C. Ghirelli, F. Raynaud, R. Hadj-Slimane, A. Cappuccio, O. Hermine, Y.J. Liu, and V. Soumelis. 2010. Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid predendritic cells (pDCs). Blood 116: 3389–3397.PubMedCrossRef

32.

Bhattacharyya, S., D.E. Brown, J.A. Brewer, S.K. Vogt, and L.J. Muglia. 2007. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 109: 4313–4319.PubMedCrossRef

Title: Possible Involvement of Toll-Like Receptors in the Pathogenesis of Myasthenia Gravis
Authors: Yu-Zhong Wang
Mei Yan
Fa-Fa Tian
Jun-Mei Zhang
Qun Liu
Huan Yang
Wen-Bin Zhou
Jing Li
Publication date: 01-02-2013
Publisher: Springer US
Published in: Inflammation / Issue 1/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-012-9526-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Possible Involvement of Toll-Like Receptors in the Pathogenesis of Myasthenia Gravis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Minocycline Treatment and Bone Marrow Mononuclear Cell Transplantation After Endothelin-1 Induced Striatal Ischemia

Opposite Effects of Quercetin, Luteolin, and Epigallocatechin Gallate on Insulin Sensitivity Under Normal and Inflammatory Conditions in Mice

Immature Dendritic Cell-Derived Exosomes: a Promise Subcellular Vaccine for Autoimmunity

Anti-inflammatory Effect of Arginase Inhibitor and Corticosteroid on Airway Allergic Reactions in a Dermatophogoides farinae-induced NC/Nga Mouse Model

Serum Levels of IL-6, IL-10, IL-12, IL-17 and IFN-γ and Their Association with Markers of Bone Metabolism in Vitamin D-Deficient Female Students

Intrahepatic Expression of Programmed Death-1 and its Ligands in Patients with HBV-Related Acute-on-Chronic Liver Failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page